



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

SPARC, Biotin Conjugate. Rabbit Antigen Immunoaffinity Purified Polyclonal

Secreted Protein Acidic and Rich in Cysteine, SPARC, SPARC-related modular calcium-binding protein 2 [Precursor], Secreted modular calcium-binding protein 2, SMOC-2, Smooth muscle-associated protein 2, SMAP-2

BACKGROUND

SPARC is a key factor in cell-matrix interactions and possibly tumour aggressiveness. The SPARC gene, which encodes a multifunctional glycoprotein with roles in tissue development, remodelling and fibrosis. A regulator of cell-extracellular matrix (ECM) interactions, SPARC represents a major factor in the ECM remodelling occurring during tumour invasion. *in silico* analysis reveals 4 UTR-SNPs located in the 3'-UTR of the SPARC gene, corresponding to 1474 g a, 1551 g c, 1922 t g and 2072 c t changes, which are significantly associated with tumoral state of the tissue. Of all hits, the 2072 SPARC polymorphism had the best association with cancer.

SPARC therefore is a gene involved in a number of diseases including rheumatoid arthritis, scleroderma, tumor development and metastasis. SPARC variants have been detected in tumour samples of patients with acute myeloblastic leukemia (AML).

IMMUNOGEN

Synthetic peptide derived from the human SPARC protein.

POSITIVE CONTROL/TISSUE EXPRESSION

Antibody has been tested on mouse heart lysate.

COMMENTS

Antibody can be used immunohistochemistry (0.5-1 µg/ml). Optimal concentration should be evaluated by serial dilutions.

ORDERING INFORMATION

CATALOG NUMBER

X2745P

SIZE

50 µg

FORM

Affinity Purified

HOST/CLONE

Rabbit

FORMULATION

Provided as ligand affinity purified antibody in phosphate buffered saline with 0.08% sodium azide

CONCENTRATION

See vial for concentration

ISOTYPE

Ig

APPLICATIONS

Immunohistochemistry

SPECIES REACTIVITY

Human SPARC, may cross react with SPARCL1

ACCESSION NUMBER

P09486, Human

PURIFICATION

Antigen Immunoaffinity Purification

SHIP CONDITIONS

Ship at ambient temperature, freeze upon arrival

STORAGE CUSTOMER

Product should be stored at -20°C. Aliquot to avoid freeze/thaw cycles

STABILITY

Products are stable for one year from purchase when stored properly

REFERENCES

1. Shi Q, et al. 'Targeting SPARC expression decreases glioma cellular survival and invasion associated with reduced activities of FAK and ILK kinases.' *Oncogene*. 2007 Jan 8; [Epub ahead of print] PMID: 17213807
2. Aouacheria A, et al. 'In silico whole-genome screening for cancer-related single-nucleotide polymorphisms located in human mRNA untranslated regions.' *BMC Genomics*. 2007 Jan 3;8(1):2 [Epub ahead of print] PMID: 17201911
3. Xue LY, et al. 'Tissue microarray analysis reveals a tight correlation between protein expression pattern and progression of esophageal squamous cell carcinoma.' *BMC Cancer*. 2006 Dec 22;6(1):296 [Epub ahead of print] PMID: 17187659
4. Arp HP, et al. 'Predicting the partitioning behavior of various highly fluorinated compounds.' *Environ Sci Technol*. 2006 Dec 1;40(23):7298-304. PMID: 17180981
5. Kelly KA, et al. 'SPARC is a VCAM-1 counter-ligand that mediates leukocyte transmigration.' *J Leukoc Biol*. 2006 Dec 18; [Epub ahead of print]
6. Markovic, S., et al. 'Tumor SPARC microenvironment signature (SMS) and plasma levels in a phase II trial of unresectable stage IV melanoma treated with *nab*-paclitaxel and carboplatin: A translational study of NCCTG trial N057E.' *J. Clin. Oncol*. 2010, Vol. 28, No. 15, 8578
7. Weiss, G.J., et al. 'Molecular characterization of interdigitating dendritic cell sarcoma.' *Rare Tumors*, 2010, 2:e50

PRODUCT SPECIFIC REFERENCES